Ver ítem 

Mostrar el registro sencillo del ítem

Gene Single Nucleotide PolymorphismAccumulation Improves Survival in Advanced Head and Neck Cancer PatientsTreated With Weekly Paclitaxel

dc.contributor.authorGRAU, JUAN-JOSE
dc.contributor.authorCaballero Borrego, Miguel
dc.contributor.authorCampayo, Marc
dc.contributor.authorSonia, Jansa
dc.contributor.authorVargas, Mauricio
dc.contributor.authorAlos, Llucia
dc.contributor.authorMONZO, MARIANO
dc.date.accessioned2026-05-29T13:54:10Z
dc.date.issued2009-08
dc.identifier.citationGrau, Juan J.; Caballero, Miguel; Campayo, Marc[et al.]. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope, 2009, 119(8), páginas 1484-1490. Disponible en <https://pubmed.ncbi.nlm.nih.gov/19504558/>. Fecha de acceso: 29 may. 2026. DOI: 10.1002/lary.20254ca
dc.identifier.issn1531-4995ca
dc.identifier.urihttps://hdl.handle.net/20.500.12328/5349
dc.description.abstractObjectives/Hypothesis: Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival. Methods: We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel. Results: SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039). Conclusions: Response rate and OS were significantly higher in patients with two or more accumulated SNPs.ca
dc.format.extent7ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofThe Laryngoscopeca
dc.relation.ispartofseries119;8
dc.rights@ 2009 The American Laryngological,Rhinological and Otological Society, Incca
dc.subject.otherHead and neck cancerca
dc.subject.otherChemotherapyca
dc.subject.otherPaclitaxelca
dc.subject.otherGenotypesca
dc.subject.otherPolymorphismsca
dc.subject.otherCàncer de cap i collca
dc.subject.otherQuimioteràpiaca
dc.subject.otherPaclitaxelca
dc.subject.otherGenotipsca
dc.subject.otherPolimorfismesca
dc.subject.otherCáncer de cabeza y cuelloca
dc.subject.otherQuimioterapiaca
dc.subject.otherPaclitaxelca
dc.subject.otherGenotiposca
dc.subject.otherPolimorfismosca
dc.titleGene Single Nucleotide PolymorphismAccumulation Improves Survival in Advanced Head and Neck Cancer PatientsTreated With Weekly Paclitaxelca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/embargoedAccess
dc.embargo.termsforeverca
dc.subject.udc616ca
dc.identifier.doihttps://dx.doi.org/10.1002/lary.20254ca
dc.date.embargoEnd9999-01-01


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Compartir en TwitterCompartir en LinkedinCompartir en FacebookCompartir en TelegramCompartir en WhatsappImprimir